生物制剂治疗对女性生育力的影响:类风湿关节炎与银屑病关节炎女性队列研究
基于电子健康记录数据库的回顾性队列研究,纳入诊断时18-40岁的4517例类风湿关节炎(RA)女性和1415例银屑病关节炎(PsA)女性,比较生物制剂暴露前后妊娠试验阳性率、妊娠尝试及体外受精(IVF)使用情况。两组诊断后阳性β-hCG率均低于诊断前基线,但生物制剂暴露未对受孕可能性产生负面影响;RA组暴露后IVF率低于治疗前(P<0.01),PsA组无显著差异。作者认为该大队列研究为生物制剂暴露者的自然及药物辅助生育力提供了令人安心的数据,仍需进一步研究及活产率数据来巩固这些发现。
要点
- 诊断后两组阳性β-hCG率均低于诊断前基线,但生物制剂暴露未对受孕可能性产生负面影响。
- 生物制剂启动后两组β-hCG检测均增加(RA P<0.01,PsA P=0.07)。
- RA组暴露后IVF率低于治疗前(P<0.01),PsA组无显著差异。
核心结论
- 该大队列研究为生物制剂暴露患者的自然及药物辅助生育力提供了令人安心的数据。
- 仍需进一步研究及活产率数据来巩固这些发现。
研究设计与样本
- 回顾性队列研究,基于电子健康记录数据库,纳入诊断时18-40岁的4517例RA女性和1415例PsA女性。
- 生物制剂治疗包括肿瘤坏死因子抑制剂、抗CD20单克隆抗体、白细胞介素阻断剂和T细胞抑制剂。
- 主要结局指标为阳性妊娠试验率,次要结局指标为妊娠尝试和体外受精(IVF)使用。
主要发现
- 诊断时平均年龄RA组30.7±6.3岁 vs PsA组30.9±6岁(P=0.260),生物制剂治疗启动时平均年龄RA组34.2±8岁 vs PsA组34.2±7.5岁(P=0.729)。
- 两组诊断后阳性β-hCG率均低于诊断前基线,但生物制剂暴露未对两组受孕可能性产生负面影响。
- 生物制剂启动后β-hCG检测增加:RA组P<0.01,PsA组P=0.07。
- 诊断前使用生育药物比例两组均约8%(P>0.5),诊断后暴露前降至两组均约4%(P>0.5),后恢复至基线值。
- RA组暴露后IVF率低于治疗前(P<0.01),PsA组无显著差异。
局限性
- 原文结论指出仍需进一步研究及活产率数据来巩固这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate female fertility in patients with rheumatoid arthritis (RA) exposed to biological drugs. METHODS: In this retrospective cohort study, based on an electronic health record database, 4517 women with RA were compared to 1415 patients with psoriatic arthritis (PsA). Patients were 18-40 years-of-age at diagnosis. Biological treatments included tumor necrosis factor inhibitors, anti-CD-20 monoclonal antibodies, interleukin blockers and T-cell inhibitors. Main outcome measure was positive pregnancy test rate. Secondary outcome measures were pregnancy attempts and use of in vitro fertilization (IVF) RESULTS: Mean age at diagnosis and at initiation of biological treatments was not statistically different between RA and PsA (30.7 ± 6.3 vs. 30.9 ± 6; p = 0.260 and 34.2 ± 8 vs. 34.2 ± 7.5 years; p = 0.729, respectively). Both groups demonstrated lower rates of positive beta hCG after diagnosis, as compared to baseline rates before diagnosis. However, exposure to biological treatment did not negatively affect the likelihood of conception in either group. Beta hCG testing increased in both groups after initiation of biological treatments (RA p < 0.01, PsA p = 0.07). Use of fertility medications before diagnosis was about 8 % in both groups (p > 0.5). After diagnosis, before exposure, this percentage dropped to approximately 4 % in both groups (p > 0.5) but recovered to baseline values. Post-exposure IVF rate among RA patients was lower (p < 0.01) than the pretreatment state but was not significantly different in the PsA group. CONCLUSIONS: This large cohort study provides reassuring data regarding spontaneous and medicated fertility in patients exposed to biological medications. Further studies, as well as data on live birth rates are required to consolidate these findings.
引用
- Herzberger EH, Hornik-Lurie T, Levi Y, et al. The effect of biological treatment on female fertility: A cohort study of women with rheumatoid arthritis and psoriatic arthritis. Semin Arthritis Rheum. 2024. PMID: 39733653. doi:10.1016/j.semarthrit.2024.152608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。